Whilst the recent acquisition of Pfizer Consumer Healthcare will act as an opportunity in its own right to promote growth for the organisation through alternative routes there is the added value capitalised through the return on investment which will be realised 12 months before plan releasing funds back into the bottom line.
Johnson and Johnson have highlighted new developments in pharma products with five undergoing regulatory review which provides the opportunity to grow the existing product portfolio.
Development into new functions of medical devices and diagnostics will provide new markets to entry which will result in business growth.
Read more: http://www.ukessays.com/essays/marketing/case-study-johnson-johnson-marketing-essay.php#ixzz3oAtbqLxL